Synlogic

📍 Cambridge, United States🗓 Founded 2014👥 79 employees💰 Last funded Sep 2014
Biotechnology Research🌐 synlogictx.com
Website LinkedIn
Synlogic is a clinical-stage biotechnology company developing a new class of biotherapeutics through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU) and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria (EH), and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic also has research collaborations established with Roche and Ginkgo Bioworks.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Synlogic?
Synlogic has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Synlogic last raise funding?
The most recent investment in Synlogic recorded on gritt.io was in September 2014.
When was Synlogic founded?
Synlogic was founded in 2014.
What industry is Synlogic in?
Synlogic operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Synlogic based?
Synlogic is headquartered in Cambridge, United States.